Sivakumar Sathasivam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sivakumar Sathasivam has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Carolyn A Young
The Walton Centre NHS Foundation Trust; Liverpool UK
2 shared publicationsDan H Moore
Research Institute; California Pacific Medical Center; San Francisco CA USA
2 shared publicationsRobert Addison-Jones
Ward 17, Department of Neurology; Royal Preston Hospital; Preston UK
2 shared publicationsRobert G Miller
Forbes Norris ALS Research Center; California Pacific Medical Center; San Francisco USA
2 shared publicationsA. Nicolson
The Walton Centre for Neurology and Neurosurgery, Liverpool, UK
1 shared publicationA. Selvan
Department of Neurophysiology, The Walton Centre for Neurology and Neurosurgery, Lower Lane, Liverpool L9 7LJ, UK
1 shared publication
Latest Publications
- 18 November 2021
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2021 (11)
Minocycline for amyotrophic lateral sclerosis or motor neuron disease
- 18 November 2021
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2021 (11)
Minocycline for amyotrophic lateral sclerosis or motor neuron disease
- Open Access
- 1 July 2011
- Published by Taylor & Francis in Therapeutics and Clinical Risk Management
- Vol. 7, 313-323
Current and emerging treatments for the management of myasthenia gravis
Peer reviewed article authored by (Sathasivam S). Read article or submit your manuscript for publishing.
- 1 July 2011
- Published by Taylor & Francis in Therapeutics and Clinical Risk Management
- Vol. 7, 313-323
Open AccessCurrent and emerging treatments for the management of myasthenia gravis
Peer reviewed article authored by (Sathasivam S). Read article or submit your manuscript for publishing.
- 20 January 2010
- Published by Wiley
- No. 1
Topiramate for treating painful neuropathy or acute or chronic pain
- 20 January 2010
- Published by Wiley
- No. 1
Topiramate for treating painful neuropathy or acute or chronic pain
- 31 July 2009
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 20 (4) , 355-358
Managing patients with amyotrophic lateral sclerosis
- 31 July 2009
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 20 (4) , 355-358
Managing patients with amyotrophic lateral sclerosis
Statin induced myopathy
How common is statin induced myopathy?In one large, population based cohort study of patients from general practices in the United Kingdom between 1991 and 1997, the mean incidence of myopathy (defined in this trial as muscle weakness and raised concentrations of creatine kinase) in patients taking statins was 1.2 per 10 000 person years (95% confidence interval 0.3 to 4.7).5 In another large study that examined rhabdomyolysis in a hospital population, the average incidence per 10 000 person years for monotherapy with atorvastatin, pravastatin, or simvastatin was 0.44 (0.20 to 0.84) and for cerivastatin was 5.34 (1.46 to 13.68).6
Statin induced myopathy
How common is statin induced myopathy?In one large, population based cohort study of patients from general practices in the United Kingdom between 1991 and 1997, the mean incidence of myopathy (defined in this trial as muscle weakness and raised concentrations of creatine kinase) in patients taking statins was 1.2 per 10 000 person years (95% confidence interval 0.3 to 4.7).5 In another large study that examined rhabdomyolysis in a hospital population, the average incidence per 10 000 person years for monotherapy with atorvastatin, pravastatin, or simvastatin was 0.44 (0.20 to 0.84) and for cerivastatin was 5.34 (1.46 to 13.68).6
- 15 September 2008
- Published by Hindawi Limited
- Vol. 62 (12) , 1920-1925
First seizure - to treat or not to treat?
The decision on whether or not to treat a first seizure is dependent on several medical and non-medical factors. In this review, we have summarised the important aspects that determine the advantages and disadvantages of treating a first seizure. We have looked at evidence from randomised controlled trials and key observational studies. There is no randomised controlled evidence that treating the aetiology of a first acute symptomatic seizure reduces the risk of relapse, although there are good biological arguments for this. For first unprovoked seizures, immediate treatment reduces the risk of seizure recurrence in the short term, but does not change the long-term prognosis for epilepsy. Other important considerations include the potential adverse events of antiepileptic drugs and socioeconomic factor such as lifestyle changes, driving, employment, financial implications and relationships. Treatment decisions can be made only on an individual patient basis after weighing the pros and cons of each case separately.
- 15 September 2008
- Published by Hindawi Limited
- Vol. 62 (12) , 1920-1925
First seizure - to treat or not to treat?
The decision on whether or not to treat a first seizure is dependent on several medical and non-medical factors. In this review, we have summarised the important aspects that determine the advantages and disadvantages of treating a first seizure. We have looked at evidence from randomised controlled trials and key observational studies. There is no randomised controlled evidence that treating the aetiology of a first acute symptomatic seizure reduces the risk of relapse, although there are good biological arguments for this. For first unprovoked seizures, immediate treatment reduces the risk of seizure recurrence in the short term, but does not change the long-term prognosis for epilepsy. Other important considerations include the potential adverse events of antiepileptic drugs and socioeconomic factor such as lifestyle changes, driving, employment, financial implications and relationships. Treatment decisions can be made only on an individual patient basis after weighing the pros and cons of each case separately.
- 20 May 2008
- Published by Springer Nature in Nature Clinical Practice Neurology
- Vol. 4 (6) , 317-327
Steroids and immunosuppressant drugs in myasthenia gravis
Nature Clinical Practice Neurology will deliver timely interpretations of key research developments, translating the latest findings into clinical practice. Our Editor-in-Chief and international Advisory Board will ensure comprehensive coverage of topical issues throughout the year, with the highest standards of editorial quality and integrity that are hallmarks of Nature Publishing Group.
- 20 May 2008
- Published by Springer Nature in Nature Clinical Practice Neurology
- Vol. 4 (6) , 317-327
Steroids and immunosuppressant drugs in myasthenia gravis
Nature Clinical Practice Neurology will deliver timely interpretations of key research developments, translating the latest findings into clinical practice. Our Editor-in-Chief and international Advisory Board will ensure comprehensive coverage of topical issues throughout the year, with the highest standards of editorial quality and integrity that are hallmarks of Nature Publishing Group.
- 1 May 2008
- Published by British Editorial Society of Bone & Joint Surgery in The Journal of Bone and Joint Surgery. British volume
- Vol. 90-B (5) , 550-553
Neuralgic amyotrophy
Neuralgic amyotrophy is an uncommon condition characterised by the acute onset of severe pain in the shoulder and arm, followed by weakness and atrophy of the affected muscles, and sensory loss as the pain subsides. The diversity of its clinical manifestations means that it may present to a variety of different specialties within medicine. This article describes the epidemiology, aetiopathogenesis, clinical features, differential diagnoses, investigations, treatment, course and prognosis of the condition.
- 1 May 2008
- Published by British Editorial Society of Bone & Joint Surgery in The Journal of Bone and Joint Surgery. British volume
- Vol. 90-B (5) , 550-553
Neuralgic amyotrophy
Neuralgic amyotrophy is an uncommon condition characterised by the acute onset of severe pain in the shoulder and arm, followed by weakness and atrophy of the affected muscles, and sensory loss as the pain subsides. The diversity of its clinical manifestations means that it may present to a variety of different specialties within medicine. This article describes the epidemiology, aetiopathogenesis, clinical features, differential diagnoses, investigations, treatment, course and prognosis of the condition.
- Open Access
- 17 April 2008
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 3 (1) , 9
Brown-Vialetto-Van Laere syndrome
The Brown-Vialetto-Van Laere syndrome (BVVL) is a rare neurological disorder characterized by progressive pontobulbar palsy associated with sensorineural deafness. Fifty-eight cases have been reported in just over 100 years. The female to male ratio is approximately 3:1. The age of onset of the initial symptom varies from infancy to the third decade. The syndrome most frequently presents with sensorineural deafness, which is usually progressive and severe. Lower cranial nerve involvement and lower and upper motor neuron limb signs are common neurological features. Other features include respiratory compromise (the most frequent non-neurological finding), limb weakness, slurring of speech, facial weakness, and neck and shoulder weakness. Optic atrophy, retinitis pigmentosa, macular hyperpigmentation, autonomic dysfunction, epilepsy may occur. The etiopathogenesis of the condition remains elusive. Approximately 50% of cases are familial, of which autosomal recessive is suggested. The remaining cases are sporadic. The diagnosis is usually based on the clinical presentation. Investigations (neurophysiological studies, magnetic resonance imaging of the brain, muscle biopsy, cerebrospinal fluid examination) are done to exclude other causes or to confirm the clinical findings. The differential diagnoses include the Fazio-Londe syndrome, amyotrophic lateral sclerosis, Nathalie syndrome, Boltshauser syndrome and Madras motor neuron disease. Treatment with steroids or intravenous immunoglobulin may result in temporary stabilization of the syndrome. However, the mainstays of management are supportive and symptomatic treatment, in particular assisted ventilation and maintenance of nutrition via gastrostomy. The clinical course of BVVL is variable and includes gradual deterioration (almost half of cases), gradual deterioration with stable periods in between (a third of cases) and deterioration with abrupt periods of worsening (just under a fifth of cases). After the initial presentation, one third of patients survive for ten years or longer.
- 17 April 2008
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 3 (1) , 9
Open AccessBrown-Vialetto-Van Laere syndrome
The Brown-Vialetto-Van Laere syndrome (BVVL) is a rare neurological disorder characterized by progressive pontobulbar palsy associated with sensorineural deafness. Fifty-eight cases have been reported in just over 100 years. The female to male ratio is approximately 3:1. The age of onset of the initial symptom varies from infancy to the third decade. The syndrome most frequently presents with sensorineural deafness, which is usually progressive and severe. Lower cranial nerve involvement and lower and upper motor neuron limb signs are common neurological features. Other features include respiratory compromise (the most frequent non-neurological finding), limb weakness, slurring of speech, facial weakness, and neck and shoulder weakness. Optic atrophy, retinitis pigmentosa, macular hyperpigmentation, autonomic dysfunction, epilepsy may occur. The etiopathogenesis of the condition remains elusive. Approximately 50% of cases are familial, of which autosomal recessive is suggested. The remaining cases are sporadic. The diagnosis is usually based on the clinical presentation. Investigations (neurophysiological studies, magnetic resonance imaging of the brain, muscle biopsy, cerebrospinal fluid examination) are done to exclude other causes or to confirm the clinical findings. The differential diagnoses include the Fazio-Londe syndrome, amyotrophic lateral sclerosis, Nathalie syndrome, Boltshauser syndrome and Madras motor neuron disease. Treatment with steroids or intravenous immunoglobulin may result in temporary stabilization of the syndrome. However, the mainstays of management are supportive and symptomatic treatment, in particular assisted ventilation and maintenance of nutrition via gastrostomy. The clinical course of BVVL is variable and includes gradual deterioration (almost half of cases), gradual deterioration with stable periods in between (a third of cases) and deterioration with abrupt periods of worsening (just under a fifth of cases). After the initial presentation, one third of patients survive for ten years or longer.